Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

IBI3001 hos deltagere med uoperable, lokalt avancerede eller metastatiske solide tumorer

22. september 2026 opdateret af: Fortvita Biologics (USA)Inc.

En fase 1/2 undersøgelse af IBI3001 i deltagere med uoperable, lokalt avancerede eller metastatiske solide tumorer

This is a Phase 1 multicenter, multi-regional, open-label, first-in-human study of IBI3001 in participants with unresectable, locally advanced or metastatic solid tumors. The purpose of this study is to identify the MTD/RP2D of IBI3001, and to explore the preliminary efficacy of IBI3001.

Studieoversigt

Status

Rekruttering

Intervention / Behandling

Undersøgelsestype

Interventionel

Tilmelding (Anslået)

250

Fase

  • Fase 1

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiekontakt

Studiesteder

    • New South Wales
      • Wollongong, New South Wales, Australien, 2500
    • South Australia
      • Adelaide, South Australia, Australien, 5000
    • California
      • Los Angeles, California, Forenede Stater, 90025
    • New Jersey
      • East Brunswick, New Jersey, Forenede Stater, 08816
    • Texas
      • Dallas, Texas, Forenede Stater, 75039
    • Virginia
      • Fairfax, Virginia, Forenede Stater, 22031
        • Aktiv, ikke rekrutterende
        • Virginia Cancer Specialists
    • Anhui
      • Hefei, Anhui, Kina, 230022
        • Rekruttering
        • The First Affiliated Hospital of Anhui Medical University
        • Kontakt:
    • Beijing Municipality
      • Beijing, Beijing Municipality, Kina, 100021
        • Rekruttering
        • Cancer Hospital, Chinese Academy of Medical Sciences
        • Kontakt:
      • Beijing, Beijing Municipality, Kina, 100853
        • Rekruttering
        • Chinese People's Liberation Army General Hospital
        • Kontakt:
    • Fujian
      • Fuzhou, Fujian, Kina, 350014
      • Fuzhou, Fujian, Kina, 350005
        • Rekruttering
        • First Affiliated Hospital, Fujian Medical University
        • Kontakt:
    • Guangxi
      • Nanning, Guangxi, Kina, 530021
        • Rekruttering
        • The Affiliated Tumor Hospital of Guangxi Medical University
        • Kontakt:
    • Heilongjiang
      • Harbin, Heilongjiang, Kina, 150081
        • Rekruttering
        • Harbin Medical University Cancer Hospital
        • Kontakt:
    • Henan
      • Anyang, Henan, Kina, 455100
      • Luoyang, Henan, Kina, 471003
        • Rekruttering
        • The First Affiliated Hospital of Henan University of Science and Technology
        • Kontakt:
      • Zhengzhou, Henan, Kina, 450008
      • Zhengzhou, Henan, Kina, 450052
        • Rekruttering
        • The First Affiliated Hospital of Zhengzhou University
        • Kontakt:
    • Hubei
      • Wuhan, Hubei, Kina, 430022
        • Rekruttering
        • Wuhan Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
        • Kontakt:
    • Hunan
      • Changsha, Hunan, Kina, 410008
        • Rekruttering
        • Xiangya Hospital, Central South University
        • Kontakt:
    • Jiangsu
      • Nanjing, Jiangsu, Kina, 210008
        • Rekruttering
        • Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University
        • Kontakt:
      • Nanjing, Jiangsu, Kina, 210029
        • Rekruttering
        • Jiangsu Province Hospital (The First Affiliated Hospital of Nanjing Medical University)
        • Kontakt:
    • Jiangxi
      • Nanchang, Jiangxi, Kina, 330029
    • Shanghai Municipality
      • Shanghai, Shanghai Municipality, Kina, 200120
        • Rekruttering
        • Shanghai East Hospital, Tongji University School of Medicine
        • Kontakt:
    • Sichuan
      • Chengdu, Sichuan, Kina, 610041
      • Chengdu, Sichuan, Kina, 610041
    • Zhejiang
      • Hangzhou, Zhejiang, Kina, 310022
      • Hangzhou, Zhejiang, Kina, 310003
        • Rekruttering
        • The First Affiliated Hospital, Zhejiang University School of Medicine
        • Kontakt:

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år og ældre (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Key Inclusion Criteria:

  1. Male or female participants ≥ 18 years old;
  2. Has an Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1;
  3. Has an anticipated life expectancy of ≥ 12 weeks;
  4. Adequate bone marrow and organ function:
  5. At least 1 evaluable lesion according to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1. for dose escalation , and 1 measurable lesion for dose expansion.
  6. Has a documented (histologically- or cytologically-proven), unresectable, locally advanced or metastatic solid tumor that is refractory to or intolerable with standard treatment, or for which no standard treatment is available; participants who refuse standard therapy, or are able to suspend standard therapy without major risks.

Key Exclusion Criteria:

  1. Progressed or refractory to an ADC that consists of an Exatecan derivative that is a topoisomerase I inhibitor or intolerable with an ADC that consists of Exatecan;
  2. Plan to receive other antitumor therapy during the study excluding palliative radiotherapy for the purpose of symptom (like pain) relief that must also not have an impact on tumor assessment throughout the study;
  3. Pyloric obstruction and/or persistent recurrent vomiting (≥ 3 times in 24 hours);
  4. Gastrointestinal perforation and/or fistula within 6 months prior to first administration of the study drug, and not recovered after surgical treatment;
  5. Known symptomatic central nervous system (CNS) metastases.
  6. History of pneumonia requiring corticosteroids therapy, or history of clinically significant lung diseases; Uncontrolled diseases;
  7. History of endotracheal or gastrointestinal stent implantation;
  8. Ascites, pleural effusion, or pericardial effusion with symptoms and requiring intervention;
  9. Esophageal or gastric varices requiring immediate intervention;
  10. Not eligible to participate in this study at the discretion of the investigator;
  11. Do not have adequate treatment washout period before study drug administration. -

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: N/A
  • Interventionel model: Enkelt gruppeopgave
  • Maskning: Ingen (Åben etiket)

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: Open-label: IBI3001 monoterapi

The provisional dose levels are planned to be evaluated, but it is possible for additional and/or intermediate dose levels to be added during the study.

IBI3001 is proposed to be administered by intravenous infusion (IV)

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Number of subjects with adverse events
Tidsramme: 24 months

Occurrence and severity of adverse events (AEs), with severity determined by NCI CTCAE v5.0 criteria

24 months
Number of subjects with clinically significant changes in physical examination results
Tidsramme: 24 months

Clinically significant abnormal physical examination findings reported by the investigator.

24 months
Number of subjects with clinically significant changes in vital signs
Tidsramme: 24 months

Vital signs including body temperature, pulse, respiratory rate, SpO2 and blood pressure

24 months
MTD or RP2D of IBI3001 Number of subjects with dose-limiting toxicities (DLTs)
Tidsramme: 24 months

Dose limiting toxicity (DLT) to establish MTD or RP2D

24 months

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Plasma concentration (Cmax) of IBI3001
Tidsramme: 24 months

Plasma concentration of IBI3001 for single and multiple doses.

24 months
Area under the curve (AUC) of IBI3001
Tidsramme: 24 months

AUC of IBI3001 for single and multiple doses

24 months
Time to maximum concentration (Tmax) of IBI3001
Tidsramme: 24 months

Tmax of IBI3001 for single and multiple doses.

24 months
Clearance (CL) of IBI3001
Tidsramme: 24 months

Clearance of IBI3001 from the plasma

24 months
Volume of distribution (V) of IBI3001
Tidsramme: 24 months

Apparent volume of distribution of IBI3001

24 months
Half-life (T1/2) of IBI3001
Tidsramme: 24 months

T1/2 of IBI3001 for single and multiple doses

24 months
Immunogenicity of IBI3001
Tidsramme: 24 months

Incidence of anti-drug (IBI3001) antibody

24 months
Objective response rate (ORR)
Tidsramme: 24 months

ORR as evaluated per the RECIST v1.1 criteria

24 months
Duration of response (DoR)
Tidsramme: 24 months

DoR as evaluated per the RECIST v1.1 criteria

24 months
Disease control rate (DCR)
Tidsramme: 24 months

DCR as evaluated per the RECIST v1.1 criteria

24 months
Time to response (TTR)
Tidsramme: 24 months

TTR as evaluated per the RECIST v1.1 criteria

24 months
Progression free survival (PFS)
Tidsramme: 24 months

PFS as evaluated per the RECIST v1.1 criteria

24 months
Overall survival (OS)
Tidsramme: 24 months

Overall survival.

24 months

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

10. januar 2025

Primær færdiggørelse (Anslået)

31. december 2026

Studieafslutning (Anslået)

31. december 2027

Datoer for studieregistrering

Først indsendt

1. april 2024

Først indsendt, der opfyldte QC-kriterier

1. april 2024

Først opslået (Faktiske)

5. april 2024

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

25. september 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

22. september 2026

Sidst verificeret

1. september 2026

Mere information

Begreber relateret til denne undersøgelse

Andre undersøgelses-id-numre

  • CIBI3001A101

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

INGEN

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ja

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner